Tag: Hyperlipidemia

Clinical studies show that between 1% and 10% of patients taking Pristiq (desvenlafaxine) may experience elevations in cholesterol and triglycerides [1.2.2]. This raises an important question for many users: can Pristiq cause high cholesterol and what does that mean for your cardiovascular health?

While diltiazem, a calcium channel blocker, generally has a neutral to potentially favorable direct effect on an individual's lipid profile, studies have confirmed that it significantly interacts with certain cholesterol-lowering medications known as statins. Understanding this crucial interaction is key to safely managing cardiovascular conditions that require both types of medication.

According to extensive product information, Lipofundin is absolutely contraindicated in patients with severe hyperlipidemia, where blood fat levels are dangerously high. Understanding the full list of contraindications for Lipofundin is critical for medical professionals to prevent severe complications during intravenous feeding.

The prevalence of dyslipidemia, or unhealthy lipid levels, is increasing globally, often necessitating combination therapy to manage both high cholesterol and high triglycerides. When prescribed to be taken together, patients must understand what are the side effects of rosuvastatin and fenofibrate together to ensure safe and effective treatment. This combination, while potent in managing mixed dyslipidemia, requires careful monitoring due to potential adverse effects on the muscles, liver, and digestive system.

Globally, high cholesterol is responsible for an estimated 4.4 million deaths each year. For patients needing significant reduction of LDL cholesterol, understanding treatment options is critical. So, **how is Evolocumab administered** to manage this risk?

In a study involving patients with atherosclerotic cardiovascular disease, the early initiation of a statin and ezetimibe combination was associated with a greater reduction in major adverse cardiovascular events compared to a delayed approach. This powerful combination addresses cholesterol from two complementary angles, offering a more robust strategy for lipid-lowering therapy and explaining why take ezetimibe and rosuvastatin together is recommended for many patients.

Antara is a brand-name medication, and its generic equivalent is fenofibrate. It is important to note that while the active ingredient is the same, different formulations of fenofibrate are not always bioequivalent, meaning they are not interchangeable without a doctor's guidance.

Contrary to the concern expressed in the question, a systematic review and meta-analysis published in 2025 found that using metronidazole led to a statistically significant reduction in total cholesterol, LDL-C, and triglycerides. The question, 'Does metronidazole increase cholesterol?', stems from a misconception, as clinical evidence consistently points toward a beneficial effect on lipid profiles during treatment.

Fenofibrate, a drug primarily known for treating high cholesterol and triglycerides, has been shown to reduce systemic inflammation markers like C-reactive protein (hsCRP) by nearly 50% in patients with metabolic syndrome. This powerful effect suggests that fenofibrate is an anti-inflammatory agent, exerting benefits beyond its standard lipid-modulating actions.

Affecting millions of people worldwide, high cholesterol and triglyceride levels are often treated with medications like fenofibrate. However, understanding **what are the main side effects of fenofibrate** is crucial for safe and effective treatment.